Clinical Trials Browser

Phase 1/2 × Has announcements × zanubrutinib × Clear all

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase 1/2 Completed

385 enrolled 29 charts 2 FDA

B-cell Malignancies